JPH0251885B2 - - Google Patents

Info

Publication number: JPH0251885B2
Authority: JP; Japan
Prior art keywords: guanhuacine; day; administered; schizophrenia; patients
Prior art date: 1981-07-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP57117908A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5823618A (ja

Inventor

Matecheku Miran

Teohaa Kaaru

Kurainroogeru Horusuto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sandoz AG

Original Assignee

Sandoz AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-07-09

Filing date

1982-07-08

Publication date

1990-11-08

1982-07-08 Application filed by Sandoz AG filed Critical Sandoz AG

1983-02-12 Publication of JPS5823618A publication Critical patent/JPS5823618A/ja

1990-11-08 Publication of JPH0251885B2 publication Critical patent/JPH0251885B2/ja

Status Granted legal-status Critical Current

Links

239000002552 dosage form Substances 0.000 claims description 5
239000012458 free base Substances 0.000 claims description 5
239000000203 mixture Substances 0.000 claims description 5
150000003839 salts Chemical group 0.000 claims description 5
201000000980 schizophrenia Diseases 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
150000001875 compounds Chemical class 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000004615 ingredient Substances 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
239000002775 capsule Substances 0.000 description 6
238000000537 electroencephalography Methods 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000008101 lactose Substances 0.000 description 4
INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 3
235000021355 Stearic acid Nutrition 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000008117 stearic acid Substances 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
208000036752 Schizophrenia, paranoid type Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000007963 capsule composition Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
230000000701 neuroleptic effect Effects 0.000 description 2
208000002851 paranoid schizophrenia Diseases 0.000 description 2
229940001470 psychoactive drug Drugs 0.000 description 2
239000004089 psychotropic agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
102100036988 Cyclin-dependent kinase 2-interacting protein Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960002048 guanfacine Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000009533 lab test Methods 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
-1 polyoxyethylene stearate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP57117908A 1981-07-09 1982-07-08 精神分裂症を治療する組成物 Granted JPS5823618A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH4512/81-4		1981-07-09
CH4512/81A CH649918A5 (de)	1981-07-09	1981-07-09	Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.

Publications (2)

Publication Number	Publication Date
JPS5823618A JPS5823618A (ja)	1983-02-12
JPH0251885B2 true JPH0251885B2 (fr)	1990-11-08

Family

ID=4277474

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP57117908A Granted JPS5823618A (ja)	1981-07-09	1982-07-08	精神分裂症を治療する組成物

Country Status (7)

Country	Link
US (1)	US4404226A (fr)
JP (1)	JPS5823618A (fr)
AU (1)	AU563446B2 (fr)
BE (1)	BE893745A (fr)
CH (1)	CH649918A5 (fr)
IT (1)	IT1189308B (fr)
PH (1)	PH19374A (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8401409D0 (sv) *	1984-03-14	1984-03-14	Astra Laekemedel Ab	New pharmaceutical preparations and a new method of alleviation of pain
US4847300A (en) *	1986-11-07	1989-07-11	Yale University	Use of alpha-2I selective adrenergic receptor agonists in memory enhancement
JP2759373B2 (ja) *	1990-05-14	1998-05-28	富士写真フイルム株式会社	カラー現像主薬及び画像形成方法
US5863934A (en) *	1995-09-21	1999-01-26	Amy F. T. Arnsten	Use of lofexidine in the treatment of behavioral disorders
US6287599B1 (en) *	2000-12-20	2001-09-11	Shire Laboratories, Inc.	Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AU2006275718B8 (en) *	2005-07-28	2012-11-01	Takeda Pharmaceutical Company Limited	Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
WO2024246786A1 (fr) *	2023-05-31	2024-12-05	Cumberland Pharmaceuticals Inc.	Formulations de guanfacine injectables et procédés

1981
- 1981-07-09 CH CH4512/81A patent/CH649918A5/de not_active IP Right Cessation
1982
- 1982-07-05 BE BE1/10549A patent/BE893745A/fr not_active IP Right Cessation
- 1982-07-06 US US06/395,724 patent/US4404226A/en not_active Expired - Fee Related
- 1982-07-07 AU AU85712/82A patent/AU563446B2/en not_active Ceased
- 1982-07-07 IT IT48764/82A patent/IT1189308B/it active
- 1982-07-08 JP JP57117908A patent/JPS5823618A/ja active Granted
- 1982-07-09 PH PH27547A patent/PH19374A/en unknown

Also Published As

Publication number	Publication date
IT1189308B (it)	1988-02-04
AU563446B2 (en)	1987-07-09
CH649918A5 (de)	1985-06-28
AU8571282A (en)	1983-01-13
US4404226A (en)	1983-09-13
BE893745A (fr)	1983-01-05
IT8248764A0 (it)	1982-07-07
PH19374A (en)	1986-04-02
JPS5823618A (ja)	1983-02-12

Publication	Publication Date	Title
KR0164435B1 (ko)	1999-01-15	비만증 치료용 약제학적 조성물
JP6137833B2 (ja)	2017-05-31	脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
WO2000002542A2 (fr)	2000-01-20	Agent a effet antidepressif
US9815827B2 (en)	2017-11-14	Agent for treatment of schizophrenia
JPH0635382B2 (ja)	1994-05-11	抗不安薬としてのフルオキセチンの使用法
EP2343976A1 (fr)	2011-07-20	Procédés d'utilisation de compositions d'aminopyridine à libération prolongée
RU2268725C2 (ru)	2006-01-27	Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
KR19990022498A (ko)	1999-03-25	뼈 손실의 최소화 방법
JPH0251885B2 (fr)	1990-11-08
KR930007252B1 (ko)	1993-08-04	우울증 치료용 약학조성물
KR100325793B1 (ko)	2002-06-20	불안신경증치료제
US20050096334A1 (en)	2005-05-05	Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome
JP2024529777A (ja)	2024-08-08	ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用
JPH0149124B2 (fr)	1989-10-23
EP2727595B1 (fr)	2018-02-21	Composition pharmaceutique pour traiter l'éjaculation prématurée et procédé pour traiter l'éjaculation prématurée
KR20230043905A (ko)	2023-03-31	5-메틸-1,2,4-옥사디아졸-3-일 화합물의 저용량 요법 및 제제
KR20010021796A (ko)	2001-03-15	선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법
Schirger et al.	1977	Prazosin—new Hypertensive Agent: A Double-Blind Crossover Study in the Treatment of Hypertension
WO2005011690A1 (fr)	2005-02-10	Utilisation de composes de 3,7-diazabicyclo[3,3,1]nonane pour traiter et/ou prevenir des evenements arythmiques chez des patients humains males
US20070202503A1 (en)	2007-08-30	Pharmaceutical Composition Of (+)-Erythro-Mefloquine And Its Use
US20050059709A1 (en)	2005-03-17	Treatment of a neuropathy with rapid release aminopyridine
JPH0343248B2 (fr)	1991-07-01
JPS6379821A (ja)	1988-04-09	卒中治療用薬剤
JPH07188002A (ja)	1995-07-25	鼻炎治療用組成物
JPH07179346A (ja)	1995-07-18	胃腸治療剤